<DOC>
	<DOC>NCT00721994</DOC>
	<brief_summary>primary endpoint of this Study is maintenance of "at least good clinical status" for a period of 10 years following initial implantation among Cormet procedures enrolled inthe pre-market IDE.</brief_summary>
	<brief_title>Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects</brief_title>
	<detailed_description>Maintaining "at least good clinical status" will be determined based upon the composite clinical success (CCS) criterion which includes no revision, removal, or replacement of any device component and a Harris Hip Total score of greater or equal to 80 points.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<criteria>subjects enrolled in the Cormet IDE study at the 5 identified clinical sites Individuals who agree to participate in the study by signing the informed patient consent form</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>hip resurfacing</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>avascular necrosis</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>